Janus Henderson Group 13F: Adds $146M to BBIO Stake

Janus Henderson Group has increased its stake in BridgeBio Pharma, Inc. (NasdaqGS:BBIO) by 19.8%, according to a Form 13F filing with the SEC. The fund added 2,178,556 shares, bringing its total holdings to 13,179,013 shares, valued at approximately $884.8 million as of the end of the first quarter of 2026.

What Changed in Janus Henderson Group's BridgeBio Pharma Position

Janus Henderson Group grew its position in BridgeBio Pharma by adding 2,178,556 shares, moving from 11,000,457 shares to a total of 13,179,013 shares. This increase represents a 19.8% change in their holdings, reflecting a substantial investment in the biotechnology company.

Other Institutional Activity in BridgeBio Pharma

In addition to Janus Henderson Group's increased stake, other institutional investors have adjusted their positions in BridgeBio Pharma. BlackRock, Inc. reduced its holdings by 341,772 shares, ending with 14,207,757 shares valued at $1.06 billion. Kohlberg Kravis Roberts & Co. L.P. maintained its position with 13,260,971 shares worth $984.8 million. Viking Global Investors LP decreased its stake by 2,551,500 shares to 11,842,434 shares, valued at $879.4 million. Meanwhile, Farallon Capital Management LLC increased its position by 367,000 shares, totaling 9,365,463 shares worth $695.5 million.

BridgeBio Pharma, Inc. Stock Holds Steady

Shares of BridgeBio Pharma (NasdaqGS:BBIO) are trading at $67.14. The company has a market capitalization of $13.18 billion and a forward P/E ratio of 135.9. Its beta is 0.975, indicating moderate volatility. The stock's 52-week range is between $38.58 and $84.94, with a 50-day moving average of $70.28 and a 200-day moving average of $67.14. The company maintains a current ratio of 1.52 and a quick ratio of 1.40.

Recent Earnings

BridgeBio Pharma reported revenue of $579.96 million, with a growth rate of 66.8%. Despite this, the company has a negative net margin of -124.4%, reflecting ongoing financial challenges. The next earnings report is expected on May 7, 2026.

Insider Buying and Selling at BridgeBio Pharma, Inc.

Recent insider activity at BridgeBio Pharma includes planned sales by CEO Neil Kumar, who sold shares on several occasions, including 40,000 shares each on June 5 and June 4, 2026, at average prices of $67.88 and $67.46, respectively. Additionally, Kumar bought 71,215 shares on May 16, 2026. President and CFO Thomas Trimarchi also sold shares, including 13,651 shares on May 18, 2026, at an average price of $65.08.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on BridgeBio Pharma, with multiple firms reiterating buy ratings. On June 3, 2026, Canaccord Genuity initiated coverage with a buy rating and a $104 price target. Citigroup initiated coverage on May 19, 2026, with a hold rating and an $82 target. Overall, the consensus is a strong buy, with a mean price target of $102.71 based on 23 analyst opinions.

About BridgeBio Pharma

BridgeBio Pharma, Inc. is a biotech company based in Palo Alto, California. It focuses on discovering and developing medicines for genetic diseases. The company has several products in development, including treatments for cardiomyopathy, molybdenum cofactor deficiency, and various genetic disorders. Founded in 2015, BridgeBio is led by CEO Dr. Neil Kumar and employs around 834 people.

Bottom Line

Janus Henderson Group's significant increase in its BridgeBio Pharma stake underscores the fund's confidence in the company's potential. Investors often monitor such 13F filings for insights into institutional strategies, though it's essential to remember these filings reflect past positions. BridgeBio's financial metrics and insider activities provide further context for those tracking the company's progress.